MedTrace Logo

Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus

NCT00395512 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 655

Last updated 2013-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.

Conditions

Interventions

DRUG

Alogliptin

Alogliptin tablets.

DRUG

Pioglitazone

Pioglitazone tablets.

DRUG

Placebo

Matching placebo tablets.

Sponsors & Collaborators

Principal Investigators

  • VP, Biological Sciences · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Bulgaria
  • Chile
  • Croatia
  • Estonia
  • Guatemala
  • Hungary
  • India
  • Israel
  • Latvia
  • Lithuania
  • Mexico
  • New Zealand
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395512 on ClinicalTrials.gov